Page 14 - Rgene Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nachricht vom 23.07.2021 | 07:01 Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin Lonza Group AG / Key word(s): Half Year Results 23-Jul-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad Hoc Release Pursuant to Art. 53 Listing Rules In H1 2021, Lonza continued its strong performance with 14.7% 1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by stro...

EQS-Adhoc: Lonza ... EQS-Adhoc: Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin vom 23.07.2021, 07:01 Uhr Bild: pixabay.com EQS Group-Ad-hoc: Lonza Group AG / Key word(s): Half Year Results Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin 23-Jul-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad Hoc Release Pursuant to Art. 53 Listing Rules In H1 2021, Lonza continued its strong perfo...

EQS-Adhoc: Lonza Group AG: Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin 23-Jul-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad Hoc Release Pursuant to Art. 53 Listing Rules In H1 2021, Lonza continued its strong performance with 14.7% 1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on g...

HIV Cure Program Releases Initial Clinical Trial Data July 15, 2021 23:51 ET | Source: American Gene Technologies American Gene Technologies Rockville, Maryland, UNITED STATES ROCKVILLE, Md., July 15, 2021 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene...

Lonza Publishes Restated Financials for 2020 Search jobs Lonza Group AG / Key word(s): Annual Results/Half Year Results 29-Jun-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Lonza reports restated 2020 financials for sales, EBIT, EBITDA and CORE EBITDA Lonza now provides 2020 financials in the redesigned business structure to reflect divisional performance   Basel, Switzerland, 29 June 2021 - Prior to the reporting of the Half-Year Results 2021 on 23 July 2021, Lonza today is providing res...